Short answer

PHIBRO ANIMAL HEALTH CORP (PAHC) filed its fiscal 2025 10-K annual report with the SEC on Aug 27, 2025. It reported revenue of $1.3B (+27.4% year over year) and net income of $48M.

Top risk flagged: Cybersecurity attacks increasing in sophistication, with potential for material business impact

FY2025 key financial metrics · XBRL

Revenue: $1.3B; +27.4% YoY
Net income: $48M; +1897.7% YoY
Operating margin: 8.5%; +3.3 pp YoY
Gross margin: 30.9%; +0.1 pp YoY
EPS (diluted): $1.19; +1883.3% YoY
ROE: 16.9%; +16.0 pp YoY
Operating cash flow: $80M; −8.5% YoY

Source: XBRL data from the PHIBRO ANIMAL HEALTH CORP (PAHC) FY2025 10-K on SEC EDGAR. USD.

PHIBRO ANIMAL HEALTH CORP FY2025 10-K analysis

AI summary of each section, grounded in the filing text

Business Overview

Core business model: Global animal health and mineral nutrition solutions for livestock and companion animals, marketing ~800 product lines across 90 countries
New acquisition: Zoetis medicated feed additive portfolio acquired for $297.5M, adding $208.2M net sales in FY25 and 6 manufacturing sites in US, Italy, China
Strategic shift: Significant expansion in Animal Health segment driven by MFA product portfolio acquisition, Animal Health sales grow 36% to $963M
Notable metric: Total net sales up 27% YoY to $1.296B; Animal Health segment EBITDA up 53% to $222M; net assets increase 39% to $1.361B
Unusual fact: Inclusion of armed conflicts’ impact on results in MD&A due to ongoing geopolitical risks in Middle East and Eastern Europe

Management Discussion & Analysis

Revenue $1.296B, up 27% YoY from $1.018B; Animal Health best segment $963M, up 36% YoY; Performance Products worst $80.2M, up 19%
Adjusted net income $84.9M, up 76% YoY from $48.4M; adjusted diluted EPS $2.09 vs $1.19 prior year
Operating margin ~8.5% ($110.5M operating income on $1,296M sales) up vs $53.3M on $1,018M (~5.2%) prior year calculated from given data
Operating cash flow $80.1M vs $87.6M prior year; Capital expenditures $38.3M vs $41.2M; Financing activities net cash inflow $207.1M (refinancing and acquisition financing); dividends paid $19.4M
Management expects adequate liquidity for next 12 months; risks include macroeconomic uncertainty, geopolitical conflicts (Israel-Hamas, Russia-Ukraine), and debt covenant restrictions on investments and dividends

Risk Factors

Cybersecurity attacks increasing in sophistication, with potential for material business impact
AI technology adoption risks, including compliance with privacy regulations and ethical use across enterprise
Dependency on third-party suppliers with ongoing cybersecurity regulatory risk monitoring and standardized risk evaluations
Key-person risk: CIO with 45 years' experience critical to information security and risk management programs
Cyber insurance coverage regularly reviewed to support layered protection against cybersecurity incidents

Generated from the filing text; verify against the original. How to read a 10-K

Other PHIBRO ANIMAL HEALTH CORP annual reports

FY2026 10-KFiled Aug 26, 2026

Ask about this 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.

Start free